<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343394">
  <stage>Registered</stage>
  <submitdate>24/08/2011</submitdate>
  <approvaldate>24/08/2011</approvaldate>
  <actrnumber>ACTRN12611000908932</actrnumber>
  <trial_identification>
    <studytitle>A study of factors affecting the concentrations of metformin in type 2 diabetic patients</studytitle>
    <scientifictitle>The clinical pharmacokinetics of metformin in patients with type 2 diabetes</scientifictitle>
    <utrn>U1111-1123-9802</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This observational study involves recruiting patients who are taking metformin for their type 2 diabetes. Patients are required to provide a minimum of 1 blood sample and a maximum of 6 blood samples on different occasions. There are no fixed timing period. Blood samples are used to determine metformin concentrations, glycosylated haemoglobin (HbA1c), creatinine and lactic acid concentration.</interventions>
    <comparator>Not applicable.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To investigate the pharmacokinetics of metformin in patients with type 2 diabetes by developing a population pharmacokinetic model.</outcome>
      <timepoint>Metformin concentrations at different occasions within a patient for intra-patient variability and metformin concentrations between patients to examine inter-patient variability. The number of metformin concentrations is not fixed, therefore can range from 1 to 6.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To investigate factors influencing the pharmacokinetics of metformin between patients. This includes the influence of kidney function (creatinine clearance), body size descriptors (weight), age and genetic polymorphisms of transporters involved in the uptake of metformin.</outcome>
      <timepoint>At the first instance for each patient.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with type 2 diabetes and taking metformin.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients unable to provide informed consent to participate in the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Convenience sample</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>6/05/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Prof Richard Day</primarysponsorname>
    <primarysponsoraddress>Dept of Clinical Pharmacology and Toxicology
Level 2, St Vincent's Hospital
390 Victoria Street
Darlinghurst NSW 2010</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>ARC Linkage Grant</fundingname>
      <fundingaddress>Level 2, 11 Lancaster Place
Majura Park ACT 2609
AUSTRALIA</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study investigates the use of metformin in patients with type 2 diabetes with an aim to develop a population pharmacokinetic model to describe the pharmacokinetics. It involves obtaining a medical history of the patient and asking patients about their metformin formulation, dose, dosing times and their compliance to the medication.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital Human Research Ethics Committee (HREC)</ethicname>
      <ethicaddress>St Vincent's Hospital
390 Victoria Street 
Darlinghurst NSW 2010</ethicaddress>
      <ethicapprovaldate>6/05/2008</ethicapprovaldate>
      <hrec>1/08/0035</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof Richard Day</name>
      <address>Dept of Clinical Pharmacology and Toxicology
Level 2 St Vincent's Hospital
390 Victoria Street
Darlinghurst NSW 2010</address>
      <phone>+61 2 8382 2304</phone>
      <fax />
      <email>r.day@unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Janna Duong</name>
      <address>Dept of Clinical Pharmacology and Toxicology
Level 2 St Vincent's Hospital
390 Victoria Street
Darlinghurst NSW 2010</address>
      <phone>+61 2 8382 2309</phone>
      <fax>+61 2 8382 2724</fax>
      <email>janna.duong@unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Janna Duong</name>
      <address>Dept of Clinical Pharmacology and Toxicology
Level 2 St Vincent's Hospital
390 Victoria Street
Darlinghurst NSW 2010</address>
      <phone>+61 2 8382 2309</phone>
      <fax />
      <email />
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>